Position in HALO
as of Jun 30, 2026
· filed Aug 17, 2026
Position Value
$1,872,844
+$375,109 QoQ
Shares Held
23,928
+3.3% QoQ
Ownership
0.021%
of shares outstanding
% of Portfolio
0.16%
of 13F equity value
Holder Rank
#250
of 667 holders
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in HALO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CENTAURUS FINANCIAL, INC. holds $5,779,268 across 11 Biotechnology names. HALO ranks #1 (32.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
This page
|
23,928 | $1,872,844 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,749 | $1,365,510 | |
| 3 | AUPH |
Aurinia Pharmaceuticals Inc.
|
65,576 | $1,112,824 | |
| 4 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
721 | $387,140 | |
| 5 | MRNA |
Moderna, Inc.
|
4,477 | $313,524 | |
| 6 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
2,454 | $272,467 | |
| 7 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
1,774 | $144,598 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
3,554 | $125,776 |
All Filings in HALO
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,872,844 | 23,928 | Shares | Sole | 2026-08-17 | |
| 2026-03-31 | $1,497,735 | 23,174 | Shares | Sole | 2026-05-18 | |
| 2025-12-31 | $1,512,904 | 22,480 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $1,634,968 | 22,293 | Shares | Sole | 2025-11-20 | |
| 2025-06-30 | $1,152,659 | 22,158 | Shares | Sole | 2025-08-29 | |
| 2025-03-31 | $1,423,920 | 22,315 | Shares | Sole | 2025-05-15 | |
| 2024-09-30 | $127,015 | 2,219 | Shares | Sole | 2024-11-12 | |
| No filing history on record for this holder in this stock. | ||||||